Published in Am J Gastroenterol on March 15, 2011
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Dig Dis Sci (2015) 1.51
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol (2015) 1.42
Predictors of Urgent Findings on Abdominopelvic CT in Patients with Crohn's Disease Presenting to the Emergency Department. Dig Dis Sci (2014) 1.40
Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf (2013) 1.31
Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology (2014) 1.14
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci (2013) 1.09
Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09
Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy (2012) 1.04
TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer (2013) 1.04
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol (2014) 0.99
Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol (2013) 0.99
Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol (2015) 0.93
Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis (2015) 0.91
Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol (2015) 0.90
Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One (2014) 0.87
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One (2015) 0.86
IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol (2015) 0.86
Promising effect of Magliasa, a traditional Iranian formula, on experimental colitis on the basis of biochemical and cellular findings. World J Gastroenterol (2013) 0.86
Diterpenoid alkaloids of Aconitum laciniatum and mitigation of inflammation by 14-O-acetylneoline in a murine model of ulcerative colitis. Sci Rep (2015) 0.84
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol (2012) 0.82
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2014) 0.81
MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. Pediatr Rheumatol Online J (2012) 0.81
Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol (2014) 0.81
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol (2014) 0.81
A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol (2011) 0.81
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol (2016) 0.81
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol (2014) 0.80
Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery. Langenbecks Arch Surg (2011) 0.79
Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. World J Gastroenterol (2013) 0.79
Inflammatory bowel disease. Middle East J Dig Dis (2012) 0.79
Serial intralesional injections of infliximab in small bowel Crohn's strictures are feasible and might lower inflammation. United European Gastroenterol J (2014) 0.79
A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation. FEBS J (2016) 0.79
Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. J Crohns Colitis (2016) 0.79
Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature. Case Rep Gastrointest Med (2014) 0.78
Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis. Gastroenterol Hepatol (N Y) (2014) 0.78
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Crotoxin from Crotalus durissus terrificus is able to down-modulate the acute intestinal inflammation in mice. PLoS One (2015) 0.78
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res (2014) 0.78
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis (2016) 0.77
Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis. PLoS One (2016) 0.77
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol (2015) 0.77
A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol (2015) 0.77
The th17/treg immune balance in ulcerative colitis patients with two different chinese syndromes: dampness-heat in large intestine and spleen and kidney yang deficiency syndrome. Evid Based Complement Alternat Med (2015) 0.77
Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.77
Ustekinumab for the treatment of Crohn's disease: can it find its niche? Therap Adv Gastroenterol (2016) 0.76
An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci (2016) 0.76
Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease. Medicine (Baltimore) (2016) 0.76
What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med (2014) 0.76
Angioedema associated with Crohn's disease: response to biologics. World J Gastroenterol (2012) 0.76
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther (2013) 0.76
Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J (2014) 0.75
Biologics in fistulizing Crohn's disease: so near, yet so far. Am J Gastroenterol (2011) 0.75
When meta-analysis misleads. Am J Gastroenterol (2011) 0.75
Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Can J Gastroenterol Hepatol (2017) 0.75
New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. Case Rep Gastroenterol (2015) 0.75
A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation. Mol Ther (2017) 0.75
Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. Clin Exp Gastroenterol (2016) 0.75
Diagnostic importance of faecal markers in long-term monitoring of anti-TNF-α therapy in primary responders with Crohn's disease. Prz Gastroenterol (2015) 0.75
Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis. Am J Transl Res (2017) 0.75
Infliximab Combined with Enteral Nutrition for Managing Crohn's Disease Complicated with Intestinal Fistulas. Gastroenterol Res Pract (2016) 0.75
(99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study. EJNMMI Res (2016) 0.75
Commentary: vedolizumab: a new mechanism of action for the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y) (2014) 0.75
Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol (2015) 0.75
Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol (2015) 0.75
Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y) (2012) 0.75
Postprandial response of bone turnover markers in patients with Crohn's disease. World J Gastroenterol (2014) 0.75
Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population. PeerJ (2014) 0.75
Biologic therapy and surgery for crohn disease. Clin Colon Rectal Surg (2013) 0.75
Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y) (2014) 0.75
Efficacy of certolizumab pegol in Crohn's disease: response to ford et Al. Am J Gastroenterol (2012) 0.75
Enterocutaneous fistula as early presentation of Crohn's disease in an adult woman. BMJ Case Rep (2012) 0.75
Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis. J Res Pharm Pract (2017) 0.75
The Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single Center Study. J Pediatr Gastroenterol Nutr (2017) 0.75
Emerging biologics in inflammatory bowel disease. J Gastroenterol (2016) 0.75
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med (2017) 0.75
Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. Eur J Clin Pharmacol (2015) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Crohn's disease. Lancet (2012) 4.42
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol (2009) 3.88
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Functional Dyspepsia. N Engl J Med (2015) 3.66
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Ulcerative colitis. Lancet (2012) 3.38
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol (2004) 3.11
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Gastro-oesophageal reflux disease. Lancet (2006) 2.96
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med (2006) 2.94
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol (2003) 2.83
Immune activation in patients with irritable bowel syndrome. Gastroenterology (2007) 2.82
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol (2007) 2.77
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc (2007) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology (2004) 2.59
Design of treatment trials for functional gastrointestinal disorders. Gastroenterology (2006) 2.58
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 2.37
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2006) 2.34
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol (2008) 2.28
G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology (2004) 2.24
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology (2009) 2.19
Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol (2013) 2.18
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol (2007) 2.14
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13